Articles tagged "Immunosuppression"

2021 American Transplant Congress
Covid vs Non Covid Pneumonia in Kidney Transplant Recipients
R. Prashar, N. Khoury, P. Shrivastava, S. Yeddula, T. Kitajima, E. Ulrich, M. Ramesh, A. Patel, S. Nagai, M. Samaniego-Picota
Henry Ford Hospital, Detroit, MI
*Purpose: Compare clinical characteristics and outcomes in kidney transplant recipients (KTRs) hospitalized with COVID vs Non COVID Pneumonia.*Methods: This is a retrospective case‐control study examining…
2021 American Transplant Congress
Avoiding Tacrolimus Under- and Overexposure with a Dosing Algorithm for Renal Transplant Recipients: A Single Arm Prospective Intervention Trial
M. I. Francke¹, L. M. Andrews², H. L. Le², J. van de Wetering¹, M. C. Clahsen-van Groningen³, T. van Gelder⁴, R. H. van Schaik⁵, B. van der Holt⁶, B. C. de Winter², D. A. Hesselink¹
¹Internal medicine, nephrology and transplantation, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ²Hospital Pharmacy, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ³Pathology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ⁴Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, Netherlands, ⁵Clinical Chemistry, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ⁶Hematology, Erasmus MC, University Medical Center, Rotterdam, Netherlands
*Purpose: Bodyweight-based tacrolimus dosing followed by therapeutic drug monitoring is standard clinical care after renal transplantation. However, after transplantation, a meagre 38% of patients is…
2021 American Transplant Congress
Peripheral Lymphocyte Profiling and Increased Risk of EBV Infection in Pediatric Liver Transplant Recipients
V. M. Novara Gennuso¹, T. Miloh²
¹Pediatrics, Miller School of Medicine- University of Miami, Miami, FL, ²Pediatrics, Miami Transplant Institute, Miami, FL
*Purpose: Epstein-Barr virus “EBV” infection and post-transplant lymphoproliferative disorders “PTLD” are significant comorbidities in the post-transplant “PT” setting, especially in pediatrics. The synergy among T…
2021 American Transplant Congress
Outcomes of Cytomegalovirus Status Determining Induction Therapy in Lung Transplant
K. Heagler¹, J. Lyons¹, B. Bemiss², P. Stracener¹
¹Pharmacy, Loyola University Medical Center, Maywood, IL, ²Loyola University Medical Center, Maywood, IL
*Purpose: At the study institution, basiliximab induction is withheld in lung transplant recipients who are cytomegalovirus (CMV) high risk due to concern for increased CMV…
2021 American Transplant Congress
Reducing Rejection in Pediatric Kidney Transplantation: The Improving Renal Outcomes Collaborative (iroc)
C. Varnell¹, A. Warmin¹, G. Barletta², C. Belsha³, L. Harshman⁴, D. Kershaw⁵, C. Pruette⁶, S. Ranabothu⁷, M. Seifert⁸, P. Singer⁹, M. Yanik¹⁰, K. Rich¹, A. Modi¹, D. Hooper¹
¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Phoenix Children’s Hospital, University of Arizona, Phoenix, AZ, ³SSM Health Cardinal Glennon Children's Hospital, St Louis, MO, ⁴University of Iowa Stead Family Children’s Hospital, Iowa City, IA, ⁵C.S. Mott Children’s Hospital, Ann Arbor, MI, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Arkansas Children’s Hospital, Little Rock, AR, ⁸University of Alabama at Birmingham, Children’s of Alabama, Birmingham, AL, ⁹Cohen Children's Hospital, Brooklyn, NY, ¹⁰Levine Children's Hospital, Charlotte, NC
*Purpose: To study the effect of implementing a Medication Adherence Promotion System (MAPS) on acute rejection (AR) rates in 9 pediatric kidney transplant (KT) programs.*Methods:…
2021 American Transplant Congress
Belatacept and Carfilzomib-based Treatment of Active Antibody-mediated Rejection in a Sensitized Nonhuman Primate Model
J. Kwun¹, R. Schmitz¹, M. Manook¹, Z. Fitch¹, D. Olaso¹, A. Choi¹, J. Yoon¹, Y. Bae¹, J. Lambris², S. Knechtle¹
¹Surgery, Duke University, Durham, NC, ²Pathology & Laboratory Medicine, University of Pennsylvania, Philadelphia, PA
*Purpose: One third of sensitized, HLA-incompatible transplant recipients experience antibody-mediated rejection (AMR) with limited effective treatment options. We tested a novel treatment strategy for AMR…
2021 American Transplant Congress
CD40/40L Pathway is Critical in Controlling CMV Transmission Following Kidney Transplantation in Immunocompromised Mice
X. Lai¹, L. Qiu², J. Wang¹, L. VanOsdol¹, S. Yan³, M. Kandpal⁴, M. Abecassis⁵, Z. Zhang¹
¹Comprehensive Transplant Center, Microsurgery core, Northwestern University, Chicago, IL, ²University of California,, San Francisco, CA, ³Northwestern University, Chicago, IL, ⁴Comprehensive Transplant Center, Northwestern University, Chicago, IL, ⁵University of Arizona, Tucson, AZ
*Purpose: We have previously shown that transplant of kidneys from donor mice latently infected with murine cytomegalovirus (CMV) into naïve recipients treated with clinically relevant…
2021 American Transplant Congress
Covid-19 Reinfection in a Kidney Transplant Patient
Z. Saeed Zafar, D. Malhotra
Nephrology, Yale School of Medicine, New Haven, CT
*Purpose: Several cases have demonstrated positive SARS-CoV-2 PCR testing in patients who were initially shown to have cleared the infection. These reinfections may represent new…
2021 American Transplant Congress
Calcineurin Inhibitor Dose and Selection, Not Antiproliferatives or Steroids, Influence Development of DSA One Year Post-kidney Transplant
M. Henderson¹, G. Morris², L. Awdishu¹, K. Fabbri¹, M. Shah³, A. Khan³, J. Kerr¹
¹Pharmacy, University of California San Diego Health, San Diego, CA, ²Pathology, University of California San Diego Health, San Diego, CA, ³Nephrology, University of California San Diego Health, San Diego, CA
*Purpose: Allograft rejection is a serious complication in kidney transplantation (KT). Despite advances in immunosuppression, acute rejection remains a concern in the first year of…
2021 American Transplant Congress
Application of Linear Discriminant Analysis (lda) to Differentiate Acute Rejection (ar) and Acute Dysfunction Non-Rejection (adnr) in Liver Transplant Recipients
M. Miller¹, R. Sinha¹, J. Weems¹, J. Holman², M. Altrich¹, S. Kleiboeker¹, J. Levitsky³
¹R&D, Viracor-Eurofins, Lee's Summit, MO, ²Transplant Genomics, Mansfield, MA, ³R&D, Northwestern University Feinberg School of Medicine, Chicago, IL
*Purpose: Blood-based biomarkers distinguishing acute-rejection (AR) from other causes of graft dysfunction (acute dysfunction non-rejection (ADNR)) would have significant clinical applicability in liver transplant (LT)…